CVRx (NASDAQ:CVRX) Announces Earnings Results

Key Points

• CVRx reported a quarterly earnings per share (EPS) of **($0.57)**, missing analysts' estimates of **($0.52)** by **$0.05** and experiencing a **negative net margin** of **97.49%**.
• Stock performance saw a slight decline, trading at **$7.55**, with a market capitalization of **$196.83 million** and an average price target of **$14.50**, indicating a **"Moderate Buy"** rating from analysts.
• Insider activity included Director Kirk G. Nielsen acquiring **10,966 shares** at an average price of **$5.45**, representing a **0.58%** ownership increase, while insiders collectively purchased **78,666 shares** valued over **$411,031** in the last quarter.

CVRx (NASDAQ:CVRX - Get Free Report) posted its earnings results on Monday. The company reported ($0.57) EPS for the quarter, missing analysts' consensus estimates of ($0.52) by ($0.05), Zacks reports. CVRx had a negative return on equity of 76.24% and a negative net margin of 95.61%. The company had revenue of $13.59 million during the quarter, compared to the consensus estimate of $13.22 million. CVRx updated its FY 2025 guidance to EPS and its Q3 2025 guidance to EPS.

CVRx Stock Performance

Shares of CVRX traded up $0.21 during mid-day trading on Wednesday, hitting $7.02. The stock had a trading volume of 251,281 shares, compared to its average volume of 328,292. The company has a market cap of $183.01 million, a PE ratio of -3.32 and a beta of 1.27. CVRx has a fifty-two week low of $4.30 and a fifty-two week high of $18.55. The company has a quick ratio of 13.45, a current ratio of 14.82 and a debt-to-equity ratio of 0.71. The company's fifty day simple moving average is $6.88 and its two-hundred day simple moving average is $9.51.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on CVRX shares. Lake Street Capital cut their price objective on CVRx from $19.00 to $14.00 and set a "buy" rating for the company in a report on Tuesday, April 8th. JPMorgan Chase & Co. reaffirmed an "underweight" rating and set a $7.00 price objective (down from $15.00) on shares of CVRx in a research report on Friday, May 9th. Canaccord Genuity Group reduced their price objective on CVRx from $23.00 to $18.00 and set a "buy" rating on the stock in a research note on Tuesday, April 8th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $11.00 price objective on shares of CVRx in a research report on Tuesday. Finally, Piper Sandler decreased their price objective on CVRx from $20.00 to $12.00 and set an "overweight" rating for the company in a research note on Friday, May 9th. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $14.00.

Insider Activity

In other news, Director Kirk G. Nielsen acquired 10,966 shares of the company's stock in a transaction dated Thursday, May 15th. The shares were bought at an average price of $5.45 per share, with a total value of $59,764.70. Following the purchase, the director owned 1,910,134 shares of the company's stock, valued at approximately $10,410,230.30. This represents a 0.58% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last 90 days, insiders purchased 78,666 shares of company stock valued at $411,031. Company insiders own 18.90% of the company's stock.

About CVRx

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.